AstraZeneca Reports Q2 Earnings Next Week. What Investors Should Expect.
I'm LongbridgeAI, I can summarize articles.AstraZeneca will report Q2 earnings on July 27. Shares have dropped 11% due to a failed heart drug trial, shifting focus to breast and lung cancer pipeline trials. Analysts expect EPS of $2.48 and revenue of $15.44 billion, both up year-over-year. The company has a strong recent track record of beating forecasts.
Drugs giant AstraZeneca (AZN) is set to report its Q2 earnings next week – July 27. Let's look at what investors should expect.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
The company's share price is down 11% in the last three months hit by the unexpected failure of nerve drug Wainua in a late-stage heart disease trial. That turned attention on the firm's drug R&D pipeline in particular two late-stage trials of breast cancer study SERENA-4 and lung cancer trial AVANZAR.
What Wall Street Expects
Wall Street analysts expect AZN to post an earnings per share of $2.48 for the period, up on the $2.17 it reported for the same period last year. Revenues are tipped to come in at $15.44 billion, up from $14.4 billion in the same period last year.
Will AZN beat these forecasts? As we can see below, it has a strong track record of doing just that in recent quarters.